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ABSTRACT 
In this research work, we built and ensembled different 
EGFR microdeletion mutations’ based Artificial Neural 
Networks(ANNs) for improved diagnosis of Non-Small Cell 
Lung Cancer(NSCLC). We developed two novel algorithms, 
namely; Genomic Nucleotide Encoding & Normalization 
(GNEN) algorithm to encode and normalize the EGFR 
nucleotides and SimMicrodel algorithm to programmatically 
simulate microdeletion mutations. Sample patients’ data with 
microdeletion mutations were extracted from online EGFR 
mutation databases and the two novel algorithms 
(implemented in MATLAB) were applied to these data to 
generate appropriate data sets for training and testing of the 
networks.   
The networks after proper training, were combined using 
minimum error voting ensembling to predict the number of 
nucleotide deletions in NSCLC patients. Using this 
ensembling approach, our simulations achieved predictions 
with minimal error and provides a basis for diagnosing 
NSCLC patients using genomics based ANN.  
Key Words: ANN, EGFR, GNEN, NSCLC, LM, 
SimMicrodel, 
1 INTRODUCTION 
Environmental and genetic factors play vital roles in the 
deveopment of any disease. However, certain human diseases 
are categorised as genetic disease or disorder because they 
are caused by abnormalities in an individual’s genetic 
materials called genome. This class of disease are of four 
different types which are; single-gene, multifactorial, 
chromosomal and mitochondrial. Meanwhile, the normal 
function of a gene is to encode a protein not to cause illness 
but genetic diseases occur when genes are unable to work 
properly. Cancer in humans generally arise from alterations 
in oncogenes, tumor suppressor gene or genes whose 
products participate in genome surveillance[1]. It can be 
considered a multifactorial disease because it results from the 
combined influence of many genetic factors acting in concert 
with environmental insults such as ultraviolet radiation, 
cigarette smoke and viruses.  
Some chemicals that are used or released via industrial 
activities such as production of plastics, asbestos, 
pharmacautical products and food supplements are not only 
mutagens but carcinogenic(cancer producing). For instance, 
chemicals that are released in smokes from cigarette imparts 
a large number of particles on the airways and alveoli of the 
human lung which slowly oxidize amd produce genotoxic 
radicals. A large percentage of lung cancers which is 
characterised by an uncontrollable growth of cells in the 
lungs are attributable to cigaratte smoking. About 85% of 
people who develop lung cancer are either smokers or have 
been smoker. Worlwid in the 21st century, lung cancers 
emerged as the leading cause of cancer deaths  because it  
results in an estimated 1.3 million deaths each year[1,2,3]. 
Pathologists determine the type of lung cancer by looking at 
a biopsy of tumor cells under the microscope. There are two 
major types of lung cancer which are; non-small cell lung 
cancer(NSCLC)  and small cell lung cancer(SCLC). NSCLC 
accounts for about 85% of lung cancers  while the remaining 
15% are SCLC[3,4]. A spectrum of mutations exists within 
the EGFR kinase domain in tumours of patients with 
NSCLC. The most frequently observed mutations are the 
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Exon 19 deletions and the Exon 21 L858R mutation, which 
taken together account for approximately 85% - 90% of all 
EGFR mutations[5,6,7]. Also, experimental studies reported 
in [8] have shown both qualitative and quantitative 
alterations in downstream signalling by mutant EGFR and 
suggested that NSCLC cells  with these mutations may be 
dependent on the altered signals for survival.  
The various mutational patterns in EGFR is a strong basis for 
an electronic based diagnosis of NSCLC using artificial 
neural network (ANN). The use of ANN in biological and 
medical researches has proliferated greatly during the last 
few years. ANN attempts to emulate function of the human 
brain and has played a great role in the fields of cancer 
research for diagnosis, prognosis and management of 
stages[12].   
Hansen et al in the early 1990 [10] shows that ANN ability 
can be significantly improved through ensembling. The most 
accepted definition of artificial neural network ensemble is 
that ANN ensemble is a collection of a finite number of 
ANNs that are trained for the same task [11]. 
Over the last two decades, a lot of research works have been 
conducted for automated cancer diagnosis based on ANN. 
Zhi-Hua Zhou et al in [13] described an approach for 
utilizing the power of ANN ensembles in reliable 
applications such as diabetes, hepatitis and breast cancer. 
Neural Network model for pattern recognition in medical 
diagnosis was described by Frenster,  J.H. in [14]. G. Wilym  
et al in [15] developed  an  efficient neural network model for 
the diagnosis of carcinogenesis. 
A system that employed an artificial neural network to detect 
suspicious regions in a low-resolution image was described 
in [18]. An automatic pathological diagnosis procedure 
named Neural Ensemble based Detection (NED)  was 
implemented with an artificial neural network ensemble  by 
Zhi-Hua Zhou et al in [19]. 
However in this work, nucleotides of the EGFR’s deletion 
mutations were utilized to train and test different ANNs. 
These ANNs are ensembled to achieve an optimal 
informatics platform for the diagnosis of NSCLC. Section 
two of this paper explains the materials and methods we 
utilised in the research, section three discusses our 
experimental results while section four draws conclusions on 
the paper. 
2. MATERIALS AND METHODS 
The Tyrosine kinase(TK) domain is the region of the EGFR 
gene that is proned to mutation in NSCLC patients. The TK 
domain has 7 exons(exons 18-24), out of which exons 18-21 
carry various somatic mutations in NSCLC patients[20]. 
The nucleotide ranges for exons 18 – 21 of the TK domain 
are shown in Table 1 
 
Table 1. Nucleotides ranges in the EGFR TK domain 
 
The benefit of artificial neural networks (ANNs) as decision 
making tools in the field of cancer was described in [16]. 
Chiou et al designed an ANN based system named 
HLND(hybrid lung cancer detection) to improve the 
accuracy of diagnosis and the speed of lung cancerous 
pulmonary radiology[17]. 
 
 
 
 
 
Table 2 details the genomic  profiles of NSCLC patients with 
microdeletion mutations that we extracted from[20]. The data 
in the table corroborate facts from other literatures on 
oncogenomics for the mutation patterns in NSCLC patients. 
From our data and from literatures, the two most common 
EGFR TK domain mutations are the in-frame deletion(2235- 
 
 
 
 
 
Exons Amino acid 
ranges 
Nucleotides 
ranges 
Number of 
bases 
18 
19 
20 
21 
687 – 728 
729 – 761 
762 – 823 
824 – 875 
2059 – 2184 
2185 - 2283 
2284 - 2469 
2470 – 2625 
126 
99 
186 
156 
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2249del or E746-A750del) in exon 19 and the 
L858R(2573T<G) missense mutation in exon 21[20,21]. 
The structural patterns for the various deletion mutations’ 
categories(Patient Category 1 to Patient Category 22) in 
Table 2  are illustrated in Figures 1,2 and 3. The deleted 
nucleotides are represented with (-).  
 
 
 
 
 
Table 2. Microdeletion mutations 
 
 
 
EGFR Gene  2059     GAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTGGGC           2157  
                       2158     TCCGGTGCGTTCGGCACGGTGTATAAG                                                                                                                                                                                                                 2184 
Patient Category 17       GAGCTTGTGGAGCCTCTTACACCCAGTGGAGAAGCTCCCAACCAAGCTCTCTTGAGGATCTTGAAGGAAACTGAATTCAAAAAGATCAAAGTGCTG - - C 
 TCCGGTGCGTTCGGCACGGTGTATAAG 
Fig 1:  Exon 18 microdeletion mutation pattern(Patient Category 17) 
 
 
 
EGFR Gene   2185        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGAT     2283 
 
Patient Category 1        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAA - - - - - - - - - - - - - - AACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 2         GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAG- - - - - - - - - - - - - - -ACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 3        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACA- - - - - - - - - - - - - - - - - - - - - - - -CTCGAT 
 
S/N Patient 
Categories 
Exons Deleted Nucleotides Number of Patients 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
19 
20 
19 
18 
19 
19 
19 
19 
19 
 
 
 
c.2235-2249del 
c.2236-2250del 
c.2254-2277del 
c.2240-2257del 
c.2240-2254del 
c.2239-2256del 
c.2237-2251del 
c.2238-2252del 
c.2238-2255del 
c.2237-2254del 
c.2239-2247del 
c.2239-2253del 
c.2245-2253del 
c.2253-2276del 
c.2309-2310del 
c.2236-2253del 
c.2155-2156del 
c.2238-2247del 
c.2254-2255del 
c.2235-2236del 
c.2240-2251del 
c.2229-2236del 
Total Patients 
166 
60 
1 
33 
6 
7 
7 
2 
2 
3 
2 
1 
1 
2 
2 
1 
1 
1 
1 
2 
3 
1 
305 
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Pateint Category 4        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAAT- - - - - - - - - - - - - - - - - -CGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 5        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAAT- - - - - - - - - - - - - - - CTCCGAAAGCCAACAAGGAAATCCTCGAT 
Patient Category 6        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAA- - - - - - - - - - - - - - - - - -CCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 7        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGG - - - - - - - - - - - - - - - CATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 8        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGA - - - - - - - - - - - - - - - ATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 9        GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGA - - - - - - - - - - - - - - - - - -TCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 10      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGG - - - - - - - - - - -  - - - - - - - CTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 11      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAA - - - - - - - - -  GCAACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 12      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAA - - - - - - - - - - - - - - - TCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 13      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGA - - - - - - - - -  TCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 14      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAAC - - - - - - - - - - - - - - - - - - - - - - - - -CTCGAT 
 
Patient Category 16      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAG - - - - - - - - - - - - - - - - - - TCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 18      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGA  - - - - - - - - - -  GCAACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 19      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAATTAAGAGAAGCAACA  - -  TCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 20      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAA  - -  AATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 21      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGCTATCAAGGAAT  - - - - - - - - - - - - CATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
 
Patient Category 22      GGACTCTGGATCCCAGAAGGTGAGAAAGTTAAAATTCCCGTCGC  - - - - - - - - AATTAAGAGAAGCAACATCTCCGAAAGCCAACAAGGAAATCCTCGAT 
Fig 2:  Exon 19 microdeletion mutation patterns(Patient Categories 1,2,3,4,5,6,7,8,9,10,11,12,13,14,16,18,19,20,21,22)  
 
 
EGFR Gene   2284        GAAGCCTACGTGATGGCCAGCGTGGACAACCCCCACGTGTGCCGCCTGCTGGGCATCTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTT   2384 
        
                        2385        CGGCTGCCTCCTGGACTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAG                                              2469 
 
 
Patient Category 15      GAAGCCTACGTGATGGCCAGCGTGG - - AACCCCCACGTGTGCCGCCTGCTGGGCATCTGCCTCACCTCCACCGTGCAGCTCATCACGCAGCTCATGCCCTT 
 
                                        CGGCTGCCTCCTGGACTATGTCCGGGAACACAAAGACAATATTGGCTCCCAGTACCTGCTCAACTGGTGTGTGCAGATCGCAAAG                                                                                                                                           
 
Fig 3:  Exon 20 microdeletion mutation pattern(Patient Category 15) 
 
 
We developed a novel algorithm for simulating each of the 
microdeletion mutations’ category programatically and 
named it SimMicrodel. The algorithm was programmed in 
MATLAB and perfectly simulates mutations for the various 
microdeletion mutated patient categories. The primary 
purpose of this algorithm is to provide a basis for computer 
based emulation of any type of micro deletion 
mutations(once the exon and the deletion range are known) 
that may be introduced into the diagnostics system randomly 
and dynamically. 
 
2.1  The Genomics Nucleotides 
Encoding and Normalization(GNEN) 
Algorithm  
To comply with the mathematical structure of each ANN 
layer, input and output data is normally structured as a string 
or vector of numbers. One of the challenges in using ANNs is 
mapping how the real-world input/output(e.g. an image, a 
physical characteristics, a list of gene names, a prognosis) 
can be mapped to a numeric vector. This is what 
normalisation caters for. A novel Genomic Nucleotides 
Encoding and Normalization(GNEN) algorithm was 
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developed by us and programmed in MATLAB to encode the 
TK domain exons for normal and mutated genes. GNEN 
encodes each nucleotide code with their ASCII equivalent 
and then subsequently normalizes the values between -1 and 
1. However, the deletionn mutation represented with(-) in the 
structural patterns are encoded as 0 (see Table 3). 
 
Table 3.  GNEN output  for the four EGFR 
nucleotides and microdeletion mutations. 
 
 
2.2 The Artificial Neural Network(ANN) 
Architecture for our Genomics Based 
ANNs 
Figure 4 is the architectural network of our genomics based 
ANN. In figure 4, p is the input vector of R x 1 dimension 
where R is the number of rows.For batch processing, p is a 
matrix. W is the weigth matrix of dimension S x R where S is 
the number of neurons in the layer. b  is the bias vector 
which is a weight with 1 as input. n is the weighted input into 
the transfer function. a  is the layer output vector. y is the 
output vector from the network. The transfer function for the 
hidden layer is tansig and for the output layer is purelin. The 
network can be built with multiple hidden layers to enhance 
it’s effectiveness. 
Therefore the following ANNs(a-c) with the respective 
inputs and outputs were built and configured in MATLAB. 
Batch processing is adopted for the training. 
a.) Exon18MicroDelANN: This has input matrix x of 
dimension 126 X 2. The elements range from x1,1 to xR,2 
where R = 126. The number of columns in the matrix is 
based on the number of patients in the training data set.  
b.) Exon19MicroDelANN: This has input matrix x of 
dimension 99 X 16. The elements range from x1,1 to xR,16 
where R = 99. 16 represents the number of patients(both 
normal and mutated) in the training data set. 
c.) Exon20MicroDelANN: This has input matrix x of 
dimension 186 X 2. The elements range from x1,1 to xR,2 
where R = 186. 2 represents the number of 
patients(normal and mutated) in the training data set. 
The output vector y has elements based on the number of 
patients in the training data set . 
If yi = 0 then the patient has non- mutated EFGR 
gene(normal). 
If yi = a (where a>0 and represent the number of deleted 
nucleotides divided by 10) the patient has microdeletion 
based mutated gene(NSCLC cancer). 
 
2.3  The Microdeletion Mutations ANNs  
Using the simulated and normalised genomic patterns with 
our novel algorithms (SimMicrodel and GNEN) and also the 
architecture in Figure 4, different ANNs were built based on 
each of the exons in EGFR’s TK domain that are susceptible 
to mutation in our sample data( exons 18 – 20). 
 
 
 
 
 
 
 
 
 
Fig 4:  Architecture of the genomics based ANN(a feed forward artificial neural network) 
Nucleotide ASCII 
Equivalent 
Normalized 
Value 
A 
C 
G 
T 
deletion(-) 
65 
67 
71 
84 
0 
-1.0000 
-0.7895 
-0.3684 
1.0000 
0 
W 
b 
+ 
W 
b 
+ 
Input 
Hidden Layer Output Layer 
p 
n 
R X 1 
S X R 
S X 1 
S X 1 
a 
n 
 
R X 
1 
S X 1 
 a = y 
a = tansig(Wp + b) 
a = y = purelin(Wa + b) 
S X R 
S X 1 
1 
1 
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3. RESULTS AND DISCUSION  
The training datasets of the genomics based ANNs are shown 
in Table 4. The target vector element for each patient 
category was obtained by the number of deleted nucleotides 
divided by 10 . 
Since the dataset is segmented into training and testing 
datasets. After proper training of the ANN with the training 
dataset and the appropriate configurations, the outcome of 
the various experiments performed by altering the number of 
hidden layers in the ANN configuration(Figure 4) and 
utilsing 
 the training datasets (Table 4) is detailed in Table 5. 
Levenberg-Marquardt algorithm was used for all the 
experiments because our study in[22] shows that it is the best 
backpropagation training algorithm for the genomics based 
ANN. 
After proper training,the various patient categories in the 
testing dataset were subjected to different configurations of 
the ANN for 5 different experiments. The outcomes of the 
tests are shown in Table 6. Table 7 shows the details of the 
errors and the minimum errors for each patient category. 
 
 
 
Table 4.  Training datasets target vector elements 
 
 
 
Table 5.  Training experiments(Expts.1 to 5) 
 
S/N Training Parameters Expt. 1 Expt.2 Expt. 3 Expt. 4 Expt.5 
1 
2 
3 
4 
5 
6 
Epoch(iterations) 
Time(seconds) 
Performance(mse) 
Gradient 
Validation check 
No of hidden layers 
6  
4 
2.45 x 10-31 
3.51 x 10-15 
0 
5 
8  
0 
0.00162 
2.45e-15 
4 
2 
6 
0 
5.73e-19 
8.52e-16 
1 
3 
8 
0 
1.92e-20 
2.44e-15 
1 
4 
5 
7 
8.2e-26 
2.06e-12 
0 
6 
 
S/N Patient categories Number of deletions Target vector elements 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
Normal Patient 
Patient Category 1 
Patient Category 3 
Patient Category 4 
Patient Category 9 
Patient Category 11 
Patient Category 13 
Patient Category 14 
Patient Category 18 
Patient Category 19 
Patient Category 21 
Patient Category 22 
0 
15 
24 
18 
18 
9 
9 
24 
10 
2 
12 
8 
0 
1.5 
2.4 
1.8 
1.8 
0.9 
0.9 
2.4 
1 
0.2 
1.2 
0.8 
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Table 6.  Testing of the ANN with different patient categories testing datasets in experiments 1-5 
  Normal 
Patient 
 
Patient 
Category 
2 
 
Patient 
Category 
5 
 
Patient 
Category 
6 
 
Patient 
Category 7 
 
Patient 
Category 8 
 
Patient 
Category 
10 
 
Patient 
Category 12 
 
Patient 
Category 16 
 
Patient 
Category 
20 
No of 
deletions 
0 15 15 18 15 15 18 15 18 2 
Expected 
Output 
0 1.5 1.5 1.8 1.5 1.5 1.8 1.5 1.8 0.2 
Expt.1 
Outputs 
0 1.36 1.5 1.83 0.89 1.37 1.34 1.57 1.31 0.93 
Expt.2 
Outputs 
0.0021 1.00 1.84 0.58 1.01 1.13 1.15 0.47 1.14 0.04 
Expt.3 
Outputs 
6.16e-10 0.85 1.09 1.94 0.59 1.33 0.45 1.43 0.82 0.67 
Expt.4 
Outputs 
5.18e-11 1.59 2.42 2.26 1.46 1.57 2.62 1.39 2.42 0.32 
Expt.5 
Outputs 
5.61e-13 1.91 1.12 1.67 1.66 1.30 1.69 1.59 2.05 0.01 
 
 
Table 7.  Experiments 1-5 errors and minimum errors 
Patient   Categories Expt.1 
Errors 
Expt.2 
Errors 
Expt.3 
Errors 
Expt.4 
Errors 
Expt.5 
Errors 
Min. 
Errors 
Normal Patient 
Patient Category 2 
Patient Category 5 
Patient Category 6 
Patient Category 7 
Patient Category 8 
Patient Category 10 
Patient Category 12 
Patient Category 16 
Patient Category 20 
0 
0.14 
0 
0.03 
0.61 
0.13 
0.46 
0.07 
0.49 
0.73 
0.0021 
0.5 
0.34 
1.25 
0.49 
0.37 
0.65 
1.1 
0.66 
0.16 
 
 
6.16e-10 
    0.65 
0.41 
0.14 
0.91 
0.17 
1.35 
0.07 
0.98 
0.47 
 
 
5.18e-11 
0.09 
0.92 
0.46 
0.04 
0.07 
0.82 
0.11 
0.62 
0.12 
 
 
5.61e-13 
0.41 
0.38 
0.13 
0.16 
0.2 
0.11 
0.09 
0.25 
0.19 
0 
0.09 
0 
0.03 
0.04 
0.07 
0.11 
0.07 
0.25 
0.12 
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In Table 8, the appropriate genomics based ANN 
configurations(i.e.experiments) for determining the number 
of mutated(deleted) nucleotides for each patient category are 
illustrated.This is based on the ANN configuration(s) that 
produced the minimum error for the patient category.  The 
training outputs for experiment 5 in MATLAB R2008a are 
shown in Figures 5,6 and 7. 
 
Table 8.  Patient categories and the appropriate ANN 
configurations(experiments) 
 
 
Fig5:  ANN training output for experiment 5 in 
MATLAB R2008a 
 
 
Fig 6:  Performance plot (mse versus epochs) for 
experiment 5 
 
Fig 7:  Regression plot for experiment 5 
4. CONCLUSION  
Tables 7 and 8 show the results of the different genomics 
based ANNs. Our results show that ensembling the ANNs 
and utilising the one with the minimum error to predict the 
number of deleted nucleotides in the cancerous patient is 
highly optimal. We therefore tag this ANN ensembling 
approach as  minimum error voting ensembling. Further 
work on this research will increase the number of 
experiments(ANN configurations) so as to obtain predictions 
that achieve almost zero error. This will further enhance the 
precision of our genomics based ANN for diagnosis of non-
small cell lung cancer(NSCLC) electronically. 
S/N Patient Categories Appropriate Experiments 
(ANN Configurations) 
1 Normal Patient Experiment 1 
2 Patient Category 2 Experiment 4 
3 Patient Category 5 Experiment 1 
4 Patient Category 6 Experiment 1 
5 Patient Category 7 Experiment 4 
6 Patient Category 8 Experiment 4 
7 Patient Category 10 Experiment 5 
8 Patient Category 12 Experiment 1 or 3 
9 Patient Category 16 Experiment 5 
10 Patient Category 20 Experiment 4 
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